Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Sex Transm Dis. 2021 Aug 1;48(8):529–535. doi: 10.1097/OLQ.0000000000001372

Figure 1.

Figure 1.

Different Chlamydia trachomatis (CT) infection prevalence measures and 95% confidence intervals (CIs) among 362 asymptomatic women enrolled in Birmingham, Alabama, 2016–2020: 1) CT nucleic acid amplification tests (NAAT) positive (+) (N = 18; 5.0%; 95% CI, 3.0%–7.7%), 2) reported prior CT infection (N = 102; 28.2%; 95% CI, 23.6%–33.1%), 3) CT NAAT+ and/or reported prior CT infection (N = 109; 30.1%; 95% CI, 25.4%–35.1%), 4) CT seropositive based on detection of CT-specific antibody by a CT elementary body ELISA (N = 230; 63.5%; 95% CI, 58.3%–68.5%), and 5) CT infection prevalence defined as the percentage of subjects with CT NAAT+, reported prior CT infection, and/or CT seropositive (N = 245; 67.7%; 95% CI, 62.6%–72.5%).